All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @claremorrow_ifbbpro on TikTok · 13s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @claremorrow_ifbbpro's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Cravings, yes. So there's a great peptide called Tessa Fenty. It is amazing. It helps with fat loss and
  2. 0:06Tremendous for your cravings as well. So if you're interested in this one, it's a pill. It's not super expensive
  3. 0:11DM me if you need them though

Tesofensine for fat loss: what the trials actually showed

Clare Morrow IFBB Pro

TikTok creator

36.1K viewsWatch on TikTok

Quick answer

Tesofensine is an investigational triple monoamine reuptake inhibitor with Phase 2 human data showing meaningful appetite suppression and weight loss, but it has not received FDA approval and carries documented cardiovascular safety concerns including elevated heart rate and blood pressure. The creator incorrectly categorized it as a peptide and offered to supply it via direct message, which raises serious legal concerns as tesofensine is not approved or legally dispensable for weight loss in the United States. Patients interested in pharmacological appetite management should consult a licensed provider about FDA-approved options with established safety profiles.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 7 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Tesofensine for fat loss: what the trials actually showed, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Video claim decision path

Turn the claim into a safer next question

Direct answer

Tesofensine for fat loss: what the trials actually showed should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.

Evidence check

Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.

Safety check

A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.

Next step

If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "Tesofensine for fat loss: what the trials actually showed" from Clare Morrow IFBB Pro. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tesofensine is an investigational triple monoamine reuptake inhibitor with Phase 2 human data showing meaningful appetite suppression and weight loss, but it has not received FDA approval and carries documented cardiovascular safety concerns including elevated heart rate and blood pressure.

The reason this review is not generic is the source wording and the canonical claim label "glp1 tesofensine is awesome to help control hunger cravings and f." In this clip, the useful excerpt is: "Cravings, yes." That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Phase 2 trial data (Astrup et al.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tesofensine is an investigational triple monoamine reuptake inhibitor with Phase 2 human data showing meaningful appetite suppression and weight loss, but it has not received FDA approval and carries documented cardiovascular safety concerns including elevated heart rate and blood pressure.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tesofensine is an investigational triple monoamine reuptake inhibitor with Phase 2 human data showing meaningful appetite suppression and weight loss, but it has not received FDA approval and carries documented cardiovascular safety concerns including elevated heart rate and blood pressure. The creator incorrectly categorized it as a peptide and offered to supply it via direct message, which raises serious legal concerns as tesofensine is not approved or legally dispensable for weight loss in the United States. Patients interested in pharmacological appetite management should consult a licensed provider about FDA-approved options with established safety profiles.
  • Tesofensine is NOT a peptide. It is a small-molecule triple monoamine reuptake inhibitor, a meaningful distinction for how it works and how it is regulated.
  • Phase 2 trial data (Astrup et al., 2008, The Lancet) showed weight loss of 6.5 to 12.8 kg over 24 weeks, which is a real signal, but no Phase 3 human trials have been completed.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Tesofensine is NOT a peptide. It is a small-molecule triple monoamine reuptake inhibitor, a meaningful distinction for how it works and how it is regulated.
  • Phase 2 trial data (Astrup et al., 2008, The Lancet) showed weight loss of 6.5 to 12.8 kg over 24 weeks, which is a real signal, but no Phase 3 human trials have been completed.
  • The same 2008 Lancet trial flagged elevated heart rate and blood pressure as safety concerns, which is a primary reason the drug's development has stalled, per Syed et al. (2023, Current Obesity Reports).
  • Tesofensine is not FDA-approved for weight loss or any other indication in the United States, meaning it cannot be legally dispensed through licensed pharmacies for this purpose.
  • Purchasing unapproved compounds via social media DMs means no verified purity, no standardized dosing, no medical oversight, and no legal protection if adverse effects occur.
  • FDA-approved GLP-1 receptor agonists like semaglutide and tirzepatide have far larger evidence bases for weight management and are available through licensed telehealth providers.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @claremorrow_ifbbpro actually say?

Clare called tesofensine "a great peptide" that is "amazing" for fat loss and "tremendous for your cravings." She described it as a pill that is "not super expensive" and invited viewers to DM her to obtain it. That last part is where things get legally and medically complicated, fast.

First, a terminology correction worth making: tesofensine is not a peptide. It is a small-molecule reuptake inhibitor, chemically distinct from peptide-based compounds like semaglutide or tirzepatide. Calling it a peptide is not just imprecise, it is factually wrong, and in a space where these distinctions affect how compounds are regulated and compounded, accuracy matters. The DM-to-purchase model she is describing is also a significant red flag for anyone thinking about patient safety and regulatory compliance.

Does the science back this up?

There is real early-phase trial data supporting tesofensine's appetite-suppressing effects, but calling it "amazing" dramatically overstates where the evidence actually stands. This drug has not cleared Phase 3 trials or received FDA approval for any indication.

The most cited human data comes from Astrup et al. (2008, The Lancet), a Phase 2 trial showing dose-dependent weight loss of 6.5 to 12.8 kg over 24 weeks compared to 2.2 kg on placebo. That is a genuinely meaningful signal. Tesofensine works by inhibiting reuptake of serotonin, dopamine, and norepinephrine, which suppresses appetite through central nervous system pathways. However, the same trial flagged elevated heart rate and blood pressure as concerns, and no large-scale Phase 3 data in humans exists publicly. A 2012 study by Lehr et al. in Obesity Reviews noted that cardiovascular safety signals kept development stalled. The mechanism is real. The "amazing" label is not yet earned by the evidence base.

What did they get wrong (or right)?

She got the core mechanism directionally right: tesofensine does appear to reduce appetite and drive weight loss in early human trials. Credit where it is due. But the errors here are not minor footnotes.

  • Calling it a peptide is flat-out incorrect. Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide. This is a basic pharmacology error.
  • Describing it as "not super expensive" with no context about sourcing, quality, or legality is irresponsible. Tesofensine is not FDA-approved and is not legally available through licensed U.S. pharmacies for weight loss. What is being sold through DMs is almost certainly a research chemical or gray-market compound with no verified purity or dosing standards.
  • Offering to supply it via direct message raises serious legal and safety concerns. Selling unapproved drugs without a valid prescriber-patient relationship and pharmacy dispensing chain is not a gray area. It is illegal under federal law.

The enthusiasm here is running well ahead of both the evidence and the regulatory reality.

What should you actually know?

Tesofensine is an investigational compound with a plausible mechanism and early positive data, not an approved weight loss drug. The distinction matters for your safety, not as regulatory bureaucracy.

The cardiovascular concerns flagged in Astrup et al. (2008) are real. Elevated heart rate and increased blood pressure were observed even in a controlled trial setting with screened participants. Obtaining this compound through social media DMs means zero quality control, no verified dosing, no medical supervision, and no recourse if something goes wrong. A 2023 review by Syed et al. in Current Obesity Reports noted that tesofensine's development pipeline remains stalled largely because of these cardiovascular safety questions.

If you are interested in medically supervised appetite management, there are FDA-approved options, including GLP-1 receptor agonists like semaglutide and tirzepatide, with far more robust trial data behind them. A licensed telehealth provider can assess whether those are appropriate for you. Buying unapproved compounds from an IFBB pro's DMs is a very different thing from medical care.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Clare Morrow IFBB Pro · TikTok creator

36.1K views on this video

Tesofensine is awesome to help control, hunger, cravings, and fat loss. #cravings #appetitecontrol #fatloss #fatlosstip

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tesofensine?

Tesofensine is NOT a peptide. It is a small-molecule triple monoamine reuptake inhibitor, a meaningful distinction for how it works and how it is regulated.

What does the video say about phase 2 trial data (astrup et al., 2008, the lancet)?

Phase 2 trial data (Astrup et al., 2008, The Lancet) showed weight loss of 6.5 to 12.8 kg over 24 weeks, which is a real signal, but no Phase 3 human trials have been completed.

What does the video say about the same 2008 lancet trial flagged elevated heart rate?

The same 2008 Lancet trial flagged elevated heart rate and blood pressure as safety concerns, which is a primary reason the drug's development has stalled, per Syed et al. (2023, Current Obesity Reports).

What does the video say about tesofensine?

Tesofensine is not FDA-approved for weight loss or any other indication in the United States, meaning it cannot be legally dispensed through licensed pharmacies for this purpose.

What does the video say about purchasing unapproved compounds via social media dms means no verified?

Purchasing unapproved compounds via social media DMs means no verified purity, no standardized dosing, no medical oversight, and no legal protection if adverse effects occur.

What does the video say about fda-approved glp-1 receptor agonists like semaglutide?

FDA-approved GLP-1 receptor agonists like semaglutide and tirzepatide have far larger evidence bases for weight management and are available through licensed telehealth providers.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Clare Morrow IFBB Pro, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.